Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Actrapid er større end risiciene ved behandling af diabetes mellitus.
The Committee for Medicinal products for Human Use (CHMP) decided that Actrapid’ s benefits are greater than its risks for the treatment of diabetes mellitus.